Clinical Trials

If you are the parent or legal guardian of a child diagnosed with recurrent osteosarcoma (a type of bone cancer that has returned), you may be eligible for a new study evaluating OST31-164, a promising investigational treatment.

Doctor examining a little girl | OS Therapies

Study Purpose

The primary goal of this study is to assess whether OST31-164 can help prevent or delay the recurrence of osteosarcoma.

Treatment Overview

Duration: Treatment involves four cycles over 48 weeks, with an intravenous infusion every three weeks. Each treatment cycle spans 12 weeks.
Follow-up: After treatment, you will receive periodic blood tests and evaluations for three years to monitor any potential infections.

Trial Locations

OS Therapies partners with top medical centers nationwide to make new osteosarcoma treatments more accessible. The locations shown on this map highlight where our clinical trials are actively taking place, offering families a nearby option to participate in this promising research.

Our technologies

What to Expect

The study drug, OST31-164, may cause mild or moderate flu-like side effects, including chills, fever, nausea, fatigue, and temporary changes in blood pressure. Side effects are generally short-lived and manageable with pre-treatment medication.

Participants will also receive antibiotics to prevent infections following each treatment session, with a blood culture check every three months during the follow-up period.

Required Tests & Procedures

Routine lab tests to monitor blood counts and health metrics

Imaging tests (MRI, CT, or X-ray) to track tumor status

Immune system analysis through periodic blood samples

Collection of previously removed tumor tissue for advanced research

These tests help us gain insights into the impact of OST31-164 on osteosarcoma and the immune system, aiming to improve outcomes for future patients.

Pediatrician meeting with parent and child | OS Therapies

Help Us Advance Osteosarcoma Research

By participating, you can contribute to our mission to identify and clinically validate new treatments for osteosarcoma. Located near NIH and FDA, OS Therapies is dedicated to advancing research in the Washington Metropolitan area’s vibrant biomedical community.